Efficacy and Safety of Oral Ambroxol on Clinical outcome in patients with neuropathic pain: A retrospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20260621002

Enrollment

Registered

2026-06-21

Start date

2024-06-01

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with neuropathic pain who are taking adequate dosage of gabapentinoid and antidepressant but still have spontaneous pain. Ambroxol Neuropathic pain Numerical Rating Scale Neuropathic Pain Symptom Inventory Patient global impression of change

Interventions

patients who received oral ambroxol 90 mg/day for 90 days

Treatment

Ambroxol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with neuropathic pain who are taking adequate dosage of gabapentinoid and antidepressant but still have spontaneous pain and have been taking 90 mg/day of oral ambroxol for at least 90 days.

Exclusion criteria

Exclusion criteria: Patients with disease progression which makes taking oral medications impossible.

Design outcomes

Primary

Measure	Time frame
Pain 0,1,3 months Pain score 0-10	—

Secondary

Measure	Time frame
Neuropathic pain symptom inventory (NPSI) 0,1,3 months NPSI score,Patient Global impression of change (PGIC) 0,1,3 months PGIC scale,Side effects of Ambroxol 0,1,3 months number of event	—

Countries

Thailand

Contacts

Public Contactpreeyaphan arunakul

Thammasat University

kpreeyap@tu.ac.th0816635144

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Jun 29, 2026